BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Badrinath N, Heo J, Yoo SY. Viruses as nanomedicine for cancer. Int J Nanomedicine 2016;11:4835-47. [PMID: 27703350 DOI: 10.2147/IJN.S116447] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Ailia MJ, Yoo SY. In Vivo Oncolytic Virotherapy in Murine Models of Hepatocellular Carcinoma: A Systematic Review. Vaccines (Basel) 2022;10:1541. [PMID: 36146619 DOI: 10.3390/vaccines10091541] [Reference Citation Analysis]
2 Nengroo MA, Verma A, Datta D. Cytokine chemokine network in tumor microenvironment: Impact on CSC properties and therapeutic applications. Cytokine 2022;156:155916. [DOI: 10.1016/j.cyto.2022.155916] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chianese A, Santella B, Ambrosino A, Stelitano D, Rinaldi L, Galdiero M, Zannella C, Franci G. Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives. Cancers (Basel) 2021;13:2761. [PMID: 34199429 DOI: 10.3390/cancers13112761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
4 Liu CH, Wong SH, Tai CJ, Tai CJ, Pan YC, Hsu HY, Richardson CD, Lin LT. Ursolic Acid and Its Nanoparticles Are Potentiators of Oncolytic Measles Virotherapy against Breast Cancer Cells. Cancers (Basel) 2021;13:E136. [PMID: 33406633 DOI: 10.3390/cancers13010136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Yoo SY, Badrinath N, Jeong SN, Woo HY, Heo J. Overcoming Tumor Resistance to Oncolyticvaccinia Virus with Anti-PD-1-Based Combination Therapy by Inducing Antitumor Immunity in the Tumor Microenvironment. Vaccines (Basel) 2020;8:E321. [PMID: 32575351 DOI: 10.3390/vaccines8020321] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
6 Jeong SN, Yoo SY. Novel Oncolytic Virus Armed with Cancer Suicide Gene and Normal Vasculogenic Gene for Improved Anti-Tumor Activity. Cancers (Basel) 2020;12:E1070. [PMID: 32344903 DOI: 10.3390/cancers12051070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
7 Lan Q, Xia S, Wang Q, Xu W, Huang H, Jiang S, Lu L. Development of oncolytic virotherapy: from genetic modification to combination therapy. Front Med 2020;14:160-84. [PMID: 32146606 DOI: 10.1007/s11684-020-0750-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
8 Yoo SY, Badrinath N, Lee HL, Heo J, Kang DH. A Cancer-Favoring, Engineered Vaccinia Virus for Cholangiocarcinoma. Cancers (Basel) 2019;11:E1667. [PMID: 31717883 DOI: 10.3390/cancers11111667] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Badrinath N, Yoo SY. Recent Advances in Cancer Stem Cell-Targeted Immunotherapy. Cancers (Basel) 2019;11:E310. [PMID: 30841635 DOI: 10.3390/cancers11030310] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
10 Howells A, Marelli G, Lemoine NR, Wang Y. Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer. Front Oncol 2017;7:195. [PMID: 28944214 DOI: 10.3389/fonc.2017.00195] [Cited by in Crossref: 57] [Cited by in F6Publishing: 69] [Article Influence: 11.4] [Reference Citation Analysis]
11 Yoo SY, Badrinath N, Woo HY, Heo J. Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma. Mediators Inflamm 2017;2017:5198798. [PMID: 28512387 DOI: 10.1155/2017/5198798] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]